Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off [Seeking Alpha]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Seeking Alpha
The company's successful commercial products include Xywav, Epidiolex, and Rylaze, which have shown increasing adoption and sales revenues. JAZZ is targeting low-hanging fruit in oncology with its drug Zanidatamab, which has the potential to become a blockbuster drug with up to $2 billion/year in net sales. Thesis I rate Jazz Pharmaceuticals ( NASDAQ: JAZZ ) as a "Buy", at this moment in time. My rating is based on its current financial health, the multiple near-term catalysts, its achievable projected growth for 2024 and 2025, and the management strategy targeting low-hanging fruit in oncology to accelerate regulatory approval. Overview Jazz Pharmaceuticals is a global pharmaceutical company headquartered in the Republic of Ireland. Currently, their most successful commercial products are Xywav (low sodium-based drug targeting narcolepsy), Epidiolex (cannabidiol-based drug against epilepsy) and Rylaze (for the treatment of acute lymphoblastic leukaemia and lymphoblastic ly
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- SUNOSI: A Dual-Acting Dopamine and Norepinephrine Reuptake Inhibitor (DNRI) for Obstructive sleep apnea (OSA) in 6MM - Market Size, Forecast, and Market Insights 2019-2032 [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024 [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024PR Newswire
- Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals Employees Wear Purple To Support Epilepsy Awareness and Community [Yahoo! Finance]Yahoo! Finance
JAZZ
Earnings
- 2/28/24 - Beat
JAZZ
Sec Filings
- 4/26/24 - Form 10-K/A
- 4/9/24 - Form 4
- 3/8/24 - Form 4
- JAZZ's page on the SEC website